Tempus AI’s (TEM) “Buy” Rating Reaffirmed at Needham & Company LLC

23 Oct 2026, 18:24 by Danessa Lincoln · The Markets Daily

Tempus AI (NASDAQ:TEM – Get Free Report)‘s stock had its “buy” rating reaffirmed by investment analysts at Needham & Company LLC in a research note issued to investors on Friday, Benzinga reports. They presently have a $75.00 price target on the stock. Needham & Company LLC‘s price target would suggest a potential upside of 11.74% from the stock’s current price.

Several other research analysts also recently commented on TEM. JPMorgan Chase & Co. lifted their price target on shares of Tempus AI from $45.00 to $70.00 and gave the stock a “neutral” rating in a research note on Wednesday, October 14th. BTIG Research increased their target price on shares of Tempus AI from $70.00 to $80.00 and gave the company a “buy” rating in a report on Thursday, August 20th. Canaccord Genuity Group lifted their target price on shares of Tempus AI from $80.00 to $95.00 and gave the stock a “buy” rating in a research report on Monday, October 12th. Lake Street Capital lowered shares of Tempus AI to a “hold” rating in a research report on Monday, July 20th. Finally, Weiss Ratings raised Tempus AI from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, October 13th. Eleven investment analysts have rated the stock with a Buy rating, nine have given a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $72.37.

View Our Latest Analysis on Tempus AI

Tempus AI Stock Up 5.2%

TEM stock traded up $3.31 during midday trading on Friday, reaching $67.12. 2,582,864 shares of the company’s stock traded hands, compared to its average volume of 6,180,179. The company has a market cap of $12.11 billion, a price-to-earnings ratio of -46.64 and a beta of 3.54. The firm’s fifty day moving average price is $68.93 and its 200-day moving average price is $57.12. The company has a quick ratio of 3.16, a current ratio of 3.30 and a debt-to-equity ratio of 3.06. Tempus AI has a 52 week low of $40.77 and a 52 week high of $93.38.

Tempus AI (NASDAQ:TEM – Get Free Report) last announced its earnings results on Thursday, July 30th. The company reported ($0.04) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.14) by $0.10. Tempus AI had a negative return on equity of 50.28% and a negative net margin of 17.77%. The company had revenue of $382.49 million for the quarter, compared to analysts’ expectations of $379.69 million. During the same quarter in the previous year, the firm earned ($0.22) earnings per share. Tempus AI’s quarterly revenue was up 21.6% on a year-over-year basis. As a group, sell-side analysts forecast that Tempus AI will post -1.38 earnings per share for the current fiscal year.

Insider Buying and Selling at Tempus AI

In other news, EVP Andrew Polovin sold 22,148 shares of the business’s stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $49.61, for a total transaction of $1,098,762.28. Following the completion of the sale, the executive vice president owned 146,067 shares of the company’s stock, valued at $7,246,383.87. The trade was a 13.17% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO James Rogers sold 26,313 shares of the company’s stock in a transaction dated Wednesday, August 19th. The stock was sold at an average price of $60.00, for a total value of $1,578,780.00. Following the completion of the sale, the chief financial officer owned 106,024 shares of the company’s stock, valued at approximately $6,361,440. The trade was a 19.88% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last quarter, insiders have sold 1,280,965 shares of company stock worth $80,397,564. 24.26% of the stock is owned by insiders.

Institutional Investors Weigh In On Tempus AI

Several institutional investors have recently made changes to their positions in the company. Ascent Wealth Partners LLC acquired a new position in shares of Tempus AI in the third quarter worth $288,000. Gibbs Wealth Management acquired a new position in Tempus AI in the third quarter valued at approximately $234,000. James J. Burns & Company LLC boosted its holdings in Tempus AI by 40.0% in the third quarter. James J. Burns & Company LLC now owns 14,002 shares of the company’s stock valued at $1,147,000 after purchasing an additional 4,000 shares in the last quarter. Wedbush Securities Inc. increased its stake in Tempus AI by 7.3% in the third quarter. Wedbush Securities Inc. now owns 10,290 shares of the company’s stock valued at $843,000 after purchasing an additional 700 shares during the last quarter. Finally, Washington Trust Advisors Inc. raised its holdings in Tempus AI by 35.7% during the third quarter. Washington Trust Advisors Inc. now owns 121,039 shares of the company’s stock worth $9,913,000 after purchasing an additional 31,873 shares in the last quarter. Institutional investors own 24.22% of the company’s stock.

Tempus AI News Summary

Here are the key news stories impacting Tempus AI this week:

Positive Sentiment: Expanded Bristol Myers Squibb relationship: Tempus and Bristol Myers Squibb reportedly expanded their collaboration through multi-year oncology and AI-data agreements. The arrangements could increase demand for Tempus’ clinical data, analytics, and AI tools while reinforcing its credibility with a major pharmaceutical company. Tempus AI Expands Bristol Myers Partnership With Multi-Year Oncology, AI Data Deals
Positive Sentiment: Neurology partnership with Pathos AI: Tempus announced an expanded data partnership with Pathos focused on neuroscience and neurology research. The agreement broadens Tempus beyond its core oncology exposure and may create additional opportunities to monetize its clinical datasets in drug development. Tempus AI Expands Neurology Data Partnership With Pathos
Positive Sentiment: Validation from Pathos’ financing: Pathos raised $237 million at a valuation of approximately $3 billion and is partnering with both Bristol Myers Squibb and Tempus. The financing and high valuation provide an external signal of investor confidence in AI-driven biomedical research and could raise the strategic profile of Tempus’ platform. AI drug firm Pathos raises $237 million, pushing valuation to $3 billion
Neutral Sentiment: Analyst commentary continues to describe Tempus as a leading AI-biotech and emphasizes its proprietary healthcare-data advantage. However, the investment case remains dependent on converting partnerships into sustained revenue and improved profitability. Tempus AI: Less Risky Than When I Said Buy
Negative Sentiment: The announcements do not appear to disclose the full financial terms or near-term earnings impact of the collaborations. Tempus remains loss-making, so investors may still focus on execution risk, partnership monetization, and its elevated valuation.

Tempus AI Company Profile

(Get Free Report)

Tempus AI, Inc is a healthcare technology company that uses artificial intelligence and data analytics to support precision medicine. The company combines clinical, molecular and imaging data to help physicians make more informed treatment decisions and to help researchers and biopharmaceutical companies develop therapies.